(Q33330549)

25 July 2017

Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial (English)

1 reference

multicenter clinical trial

25 July 2017

phase II clinical trial

0 references

0 references

author name string

M Van Kooten

1

1 reference

25 July 2017

G Traine

2

1 reference

25 July 2017

G Cinat

3

1 reference

25 July 2017

E Cazap

4

1 reference

25 July 2017

A Z Comba

5

1 reference

25 July 2017

H Vicente

6

1 reference

25 July 2017

S Sena

7

1 reference

25 July 2017

O R Nievas

8

1 reference

25 July 2017

M Orlando

9

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

British Journal of Cancer

25 July 2017

1 reference

25 July 2017

81

1 reference

25 July 2017

5

1 reference

25 July 2017

846-849

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690774

25 July 2017

0 references

cites work

Management strategies for recurrent non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

Chemotherapy of lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374290

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

21 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/10555756

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6690774

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference